Back

Kali Therapeutics named to 2026 Endpoints 11 biotechnology company list

Verifying
  • Kali Therapeutics won recognition in the 2026 Endpoints 11 biotechnology company selection.
  • KT501 generated $180 million upfront and near-term payments in its Sanofi license.
  • Kali began Phase 1a rheumatoid arthritis dosing for KT501 in March 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.